- Sales of €4.2 billion and 4.5% growth at constant exchange rate that confirm the increase in the number of patients treated with our drugs worldwide. Servier’s sales comprise €2.9 billion for brand drugs (+3% at constant rate) and €1.3 billion for generic drugs (+8% at constant rate).
- An operating income that is 7.4% of sales is explained by Servier’s ambition to drive its development by investing internationally and by patent expiries.
- 22 000 employees, 5000 in France and 17 000 internationally.
- An international presence accounting for 93% of sales, excluding generics.
- An acknowledged leader in cardiology, with €2.1 billion, i.e., 71% of consolidated sales, excluding generics.
- Implementation of Servier’s strategic priorities, notably our acquisition of the oncology branch of Shire (for $2.4 billion), which enables us to establish a direct business presence in the United States and to grow our range of cancer drugs. In France, progress in projects concerning the Institut de Recherche Servier de Paris-Saclay and the biopharmaceutical production unit at Gidy also illustrate the implementation of Servier’s strategic priorities.
Paris, France – 31 January 2019 – Servier, an independent international pharmaceutical company, announced its sales figures for the 2017-2018 financial year and reviewed the highlights of its business activities.
Sustained growth in sales volume
Servier Group’s sales for the 2017-2018 financial year were €4.2 billion. This figure results, notably, from an 8% increase in the volume of sales of our drugs, attenuated by unfavorable effects of pricing and foreign currency rates, due to Servier’s strong presence outside the eurozone, and by patent expiries, notably in Canada and in all countries for Procoralan®. This explains that at the real exchange rate, sales growth was 0.6%.
Brand drug sales (€2.9 billion) account for 69% of consolidated sales and sales of generics for 31% (€1.3 billion).
Two new brand drugs have performed very well: sales of Lonsurf®, used for the treatment of metastatic colorectal cancer, have grown by over 62%, and Triplixam®, a cardiovascular drug, has seen sales increase by 39%.